Cite
HARVARD Citation
Takeuchi, S. et al. (2020). Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Cancer science. 111 (2), pp. 561-570. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Takeuchi, S. et al. (2020). Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer. Cancer science. 111 (2), pp. 561-570. [Online].